Rosiglitazone/Metformin

Drugs

Volumn 65, Issue 11, 2005, Pages 1581-1592

  Wellington, Keri ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CYTOCHROME P450 2C8; CYTOCHROME P450 INHIBITOR; DIGOXIN; ENZYME INDUCING AGENT; FUROSEMIDE; GEMFIBROZIL; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MORPHINE; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA;

ABDOMINAL PAIN; BIOEQUIVALENCE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERABILITY; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; INSULIN SENSITIVITY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANIMALS; DIABETES MELLITUS; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; THERAPEUTIC EQUIVALENCY; THIAZOLIDINEDIONES;

EID: 23744434472     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565110-00013     Document Type: Review

References (45)

1. Hawkins D, Bradberry JC, Cziraky MJ, et al. National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy 2002 Apr; 22 (4): 436-44
2. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62 (12): 1805-37
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28 Suppl. 1: S37-42
4. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995 May; 49 (5): 721-49
5. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003; 63 (18): 1879-94
6. Cox SL. Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes. Drugs Today (Barc) 2004 Jul; 40 (7): 633-43
7. Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004 Dec; 26 (12): 2066-75
8. Del Prato S, Volpe L. Rosiglitazone plus metformin: combination therapy for type 2 diabetes. Expert Opin Pharmacother 2004; 5 (6): 1411-22
9. Kunhiraman B, Itoua-Nganongo W, Fonseca V. Avandamet. Br J Diabetes Vasc Dis 2004; 4: 268-71
10. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63 (13): 1373-405
11. Bailey CJ, Day C. Avandamet: combined metformin-rosig litazone treatment for insulin resistance in type 2 diabetes. Int J Clin Pract 2004 Sep; 58 (9): 867-76
12. Karlsson HKR, Hällsten K, Björnholm M, et al. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 2005 May; 54 (5): 1459-67
13. Shargorodsky M, Wainstein G, Gavish E, et al. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003 Aug; 16 (8): 617-22
14. Ovalle F, Bell DSH. Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes. Diabetes Care 2004 Nov; 27 (11): 2585-9
15. Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004 Apr; 286 (4): E560-7
16. Tiikkainen M, Häkkinen A-M, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004 Aug; 53 (8): 2169-76
17. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002 Aug 6; 106 (6): 679-84
18. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003 Feb; 23: 283-8
19. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003 Apr 22; 107: 1954-7
20. Yosefy C, Magen E, Kiselevich A, et al. Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004 Aug; 44 (2): 215-22
21. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004 Sep; 22 (9): 1769-77
22. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004 Jun; 27 (6): 1349-57
23. Honisett SY, Stojanovska L, Sudhir K, et al. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes [letter]. Diabetes Care 2003 Nov; 26 (11): 3194-5
24. Regensteiner JG, Bauer TA, Reusch JB. Rosiglitazone improves exercise capacity in type 2 diabetes (T2DM) [abstract no. 35-OR]. Diabetes 2004 Jun; 53 Suppl. 2: A8-9
25. Petrofsky JS, Bweir SO, Lee SW, et al. Rosiglitazone improves age related reductions in forearm resting flows and endothelial dysfunction observed in type 2 diabetes [abstract no. P3022]. Eur Heart J 2004; 25 (Abstr. Suppl.): 512-3
26. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000 Apr 5; 283 (13): 1695-702
27. Gómez-Perez FJ, Fanghänel-Salmón G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-34
28. GlaxoSmithKline. Avandamet® (rosiglitazone maleate and metformin hydrochloride) tablets [online]. Available from URL: http://us.gsk.com [Accessed 2005 May 4]
29. Zarich SW. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. Rev Cardiovasc Med 2003; 4 Suppl. 6: S19-8
30. Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes: effects on development and progression. Postgrad Med 2001 Apr; 109 (4): 55-9, 63-4
31. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002 Feb; 51 Suppl. 1: S134-7
32. Weissman PN, Goldstein BJ, Campbell JC, et al. Rosiglitazone plus metformin combination effects on CV risk markers suggest potential CV benefits in type 2 diabetic patients [abstract no. 121-OR]. Diabetes 2004 Jun; 53 Suppl. 2: 28
33. Derosa G, Gaddi AV, Piccinni MN, et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy 2005 May; 25 (5): 637-45
34. Bakris GL, Ruilope LM, Weston WM, et al. Rosiglitazone (RSG) added to metformin (MET) reduces urinary albumin/creatinine ratio and ambulatory blood pressure in subjects with microalbuminuria and type 2 diabetes (T2DM) [abstract no. 543-P]. Diabetes 2005 Jun; 54 Suppl. 1: A134
35. Di Cicco RA, Allen A, Carr A, et al. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol 2000 Nov; 40 (11): 1280-5
36. US FDA Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number 21-410 [online]. Available from URL: http://www.f-da.gov/cder/foi/nda/2002/21-410_Avandamet_BioPharmr.pdf [Accessed 2005 May 4]
37. Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000 Jul; 28 (7): 772-80
38. GlaxoSmithKline. Avandamet: summary of product characteris tics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/avandamet/ avandamet.htm [Accessed 2005 May 2]
39. Stewart M, Bailey C, Andrew D, et al. Rosiglitazone/metformin (RSG/MET) fixed dose combination (AVM) is associated with attainment of glycaemic targets for a greater proportion of patients with type 2 diabetes (T2DM) than uptitrated MET. Diabet Med 2005; 22 Suppl. 2: 48.
40. Plus poster presented at the Diabetes UK Annual Professional Conference; 2005 Apr 20-22; Glasgow
41. Rosenstock J, Stow L, Rood J, et al. Rosiglitazone/metformin (RSG/MET) fixed dose combination (FDC) is effective and well-tolerated in drug-naive type 2 diabetes mellitus (T2DM) subjects with severe hyerglycemia [abstract no. 515-P]. Diabetes 2005 Jun; 54 Suppl. 1: A127
42. Maheux P, Berry RA, Warsi G, et al. Rosiglitazone-metformin combination improves glycemic control in patients with type 2 diabetes [poster no. 168]. 5th Annual Professional Conference of the Canadian Diabetes Association and the Canadian Society of Endocrinology and Metabolism CDA/CSEM; 2001 Oct 17-20; Edmonton, 168
43. Garber A, Sankoh S, Mohideen P, et al. Glyburide/metformin tablets versus metformin plus rosiglitazone in type 2 diabetes patients uncontrolled on metformin: attaining glycemic goals [abstract no. 513-P]. Diabetes 2003 Jun; 52 Suppl. 1: 119-20.
44. Plus poster presented at the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans
45. Home PD, Pocock S, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): an interim analysis of glycaemia at 18 months [poster no. 725]. 40th Annual Meeting of the European Association for the Study of Diabetes; 2004 Sep 5-9; Munich